NASDAQ:NEO NeoGenomics - NEO Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding NeoGenomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $12.36 -0.33 (-2.60%) (As of 02/3/2023 10:46 AM ET) Add Compare Share Share Today's Range$12.24▼$12.5150-Day Range$8.92▼$12.6952-Week Range$6.00▼$23.78Volume82,064 shsAverage Volume761,107 shsMarket Capitalization$1.56 billionP/E RatioN/ADividend YieldN/APrice Target$19.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media NeoGenomics MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside53.1% Upside$18.92 Price TargetShort InterestHealthy3.51% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.52Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.86) to ($0.67) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.42 out of 5 starsMedical Sector176th out of 1,029 stocksTesting Laboratories Industry1st out of 1 stocks 4.3 Analyst's Opinion Consensus RatingNeoGenomics has received a consensus rating of Buy. The company's average rating score is 2.58, and is based on 7 buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $18.92, NeoGenomics has a forecasted upside of 53.1% from its current price of $12.36.Amount of Analyst CoverageNeoGenomics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.51% of the outstanding shares of NeoGenomics have been sold short.Short Interest Ratio / Days to CoverNeoGenomics has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NeoGenomics has recently decreased by 1.34%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldNeoGenomics does not currently pay a dividend.Dividend GrowthNeoGenomics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NEO. Previous Next 2.0 News and Social Media Coverage News SentimentNeoGenomics has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for NeoGenomics this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for NEO on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added NeoGenomics to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NeoGenomics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.00% of the stock of NeoGenomics is held by insiders.Percentage Held by Institutions88.15% of the stock of NeoGenomics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for NeoGenomics are expected to grow in the coming year, from ($0.86) to ($0.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NeoGenomics is -9.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NeoGenomics is -9.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeoGenomics has a P/B Ratio of 1.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About NeoGenomics (NASDAQ:NEO) StockNeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials and research. It also provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.Read More Receive NEO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeoGenomics and its competitors with MarketBeat's FREE daily newsletter. Email Address NEO Stock News HeadlinesFebruary 3, 2023 | americanbankingnews.comNeoGenomics (NASDAQ:NEO) Rating Increased to Buy at Needham & Company LLCFebruary 1, 2023 | benzinga.comNEO Investors Have Opportunity to Lead NeoGenomics, Inc. Securities Fraud LawsuitFebruary 3, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.January 30, 2023 | americanbankingnews.comBrokerages Set NeoGenomics, Inc. (NASDAQ:NEO) Price Target at $18.70January 27, 2023 | americanbankingnews.comComparing NeoGenomics (NASDAQ:NEO) and BioNano Genomics, Inc. WT EXP 082123 (NASDAQ:BNGOW)December 12, 2022 | finance.yahoo.comWall Street Analysts Predict a 41% Upside in NeoGenomics (NEO): Here's What You Should KnowNovember 21, 2022 | finance.yahoo.comRaDaR(R) Assay Demonstrates Clinical Potential for Detecting Disease Recurrence Across All Types of Early Breast Cancer, Including Triple Negative DiseaseNovember 18, 2022 | finance.yahoo.comNeoGenomics and ImmunoGen Launch New Program Giving Ovarian Cancer Patients Access to Novel FR Biomarker Testing to Support the Launch of ELAHERE(TM)February 3, 2023 | Investing Trends (Ad)Apple, Amazon, and Walmart are Investing in Solar EnergyThe global market for solar energy is expected to be worth an astronomical $1 trillion by the end of 2028, with increasing adoption of solar by commercial, non-profit, and public entities. Even Fortune 500 companies such as Apple, Amazon, and Walmart are investing in solar to help save money over the long term. So it's little wonder solar is also becoming one of the fastest growing sectors in the U.S. stock market.November 17, 2022 | nasdaq.comBullish Two Hundred Day Moving Average Cross - NEONovember 11, 2022 | finance.yahoo.comNeoGenomics Third Quarter 2022 Earnings: Beats ExpectationsNovember 11, 2022 | finance.yahoo.comWhy Shares of NeoGenomics Jumped 53.9% This WeekNovember 8, 2022 | finance.yahoo.comNeoGenomics (NEO) Reports Q3 Loss, Tops Revenue EstimatesNovember 8, 2022 | finance.yahoo.comNeoGenomics Reports Third Quarter 2022 ResultsNovember 7, 2022 | finance.yahoo.comNeoGenomics Appoints David Perez, Industry Veteran and Former Terumo BCT CEO, to Its Board of DirectorsOctober 28, 2022 | finance.yahoo.comNeoGenomics Provides Update on MolDX Submission for CRC and RaDaR(TM) Commercial LaunchOctober 19, 2022 | finance.yahoo.comGlobal Anatomic Pathology Market Research Report 2021-2032 - Yahoo FinanceOctober 13, 2022 | finance.yahoo.comNeoGenomics Schedules its Third Quarter 2022 Earnings Release for November 8, 2022 - Yahoo FinanceOctober 13, 2022 | finance.yahoo.comNeoGenomics Schedules its Third Quarter 2022 Earnings Release for November 8, 2022October 12, 2022 | globenewswire.comAt 9% CAGR, Global Anatomic Pathology Market Size Surpass USD USD 59424 Million By 2033; Increasing Prevalence of Cancer and Rising Number of Pathologists to Elevate Market Growth - Research Nester - GlobeNewswireOctober 12, 2022 | finance.yahoo.comShareholders in NeoGenomics (NASDAQ:NEO) have lost 82%, as stock drops 19% this past weekOctober 6, 2022 | businesswire.comGlobal Bioinformatics Market Report to 2027 - Featuring BGI, Perkin Elmer, NeoGenomics Laboratories and Illumina Among Others - ResearchAndMarkets.com - Business WireOctober 5, 2022 | fool.comNeoGenomics, Inc. (NASDAQ: NEO)September 30, 2022 | seekingalpha.comNeoGenomics Stock: Market Punishment Continues, But Looks Justified (NASDAQ:NEO) - Seeking AlphaSeptember 30, 2022 | finance.yahoo.comHere’s How Artisan Partners Views NeoGenomics (NEO)September 30, 2022 | finance.yahoo.comBiognosys Expands Its Global Presence with a US Office in Biopharma Hub Cambridge, MassachusettsSeptember 11, 2022 | businesswire.comClinical Biomarkers Markets, 2031 - ResearchAndMarkets.com - Business WireSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive NEO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeoGenomics and its competitors with MarketBeat's FREE daily newsletter. Email Address NEO Company Calendar Last Earnings11/08/2022Today2/03/2023Next Earnings (Estimated)2/22/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Testing laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NEO CUSIPN/A CIK1077183 Webwww.neogenomics.com Phone(239) 768-0600Fax239-690-4237Employees2,000Year FoundedN/APrice Target and Rating Average Stock Price Forecast$18.92 High Stock Price Forecast$30.00 Low Stock Price Forecast$12.00 Forecasted Upside/Downside+53.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($1.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,350,000.00 Net Margins-32.88% Pretax Margin-35.84% Return on Equity-9.46% Return on Assets-5.54% Debt Debt-to-Equity Ratio0.53 Current Ratio7.10 Quick Ratio6.82 Sales & Book Value Annual Sales$484.33 million Price / Sales3.22 Cash Flow$0.19 per share Price / Cash Flow66.06 Book Value$9.00 per share Price / Book1.37Miscellaneous Outstanding Shares126,300,000Free Float125,040,000Market Cap$1.56 billion OptionableOptionable Beta1.18 Key ExecutivesChris SmithChief Executive OfficerJeffrey Scott ShermanChief Financial OfficerSteven A. RossChief Information Officer & Vice PresidentDavid SholehvarPresident-Clinical ServicesJohn MooneyChief Technology OfficerKey CompetitorsDay One BiopharmaceuticalsNASDAQ:DAWNVerona PharmaNASDAQ:VRNAEmbectaNASDAQ:EMBCOwens & MinorNYSE:OMICatalyst PharmaceuticalsNASDAQ:CPRXView All CompetitorsInsiders & InstitutionsNisa Investment Advisors LLCBought 2,500 shares on 2/2/2023Ownership: 0.041%SG Americas Securities LLCSold 151,048 shares on 2/2/2023Ownership: 0.024%ProShare Advisors LLCBought 2,579 shares on 2/2/2023Ownership: 0.016%Simplex Trading LLCSold 44,300 shares on 2/2/2023Ownership: 0.000%CWM LLCBought 2,106 shares on 2/1/2023Ownership: 0.003%View All Insider TransactionsView All Institutional Transactions NEO Stock - Frequently Asked Questions Should I buy or sell NeoGenomics stock right now? 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last year. There are currently 5 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NEO shares. View NEO analyst ratings or view top-rated stocks. What is NeoGenomics' stock price forecast for 2023? 12 analysts have issued twelve-month target prices for NeoGenomics' shares. Their NEO share price forecasts range from $12.00 to $30.00. On average, they predict the company's stock price to reach $18.92 in the next twelve months. This suggests a possible upside of 49.1% from the stock's current price. View analysts price targets for NEO or view top-rated stocks among Wall Street analysts. How have NEO shares performed in 2023? NeoGenomics' stock was trading at $9.24 at the beginning of 2023. Since then, NEO shares have increased by 37.3% and is now trading at $12.69. View the best growth stocks for 2023 here. When is NeoGenomics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023. View our NEO earnings forecast. How were NeoGenomics' earnings last quarter? NeoGenomics, Inc. (NASDAQ:NEO) released its quarterly earnings data on Tuesday, November, 8th. The medical research company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.06. The medical research company earned $128.78 million during the quarter, compared to analysts' expectations of $122.55 million. NeoGenomics had a negative net margin of 32.88% and a negative trailing twelve-month return on equity of 9.46%. What is Douglas M. VanOort's approval rating as NeoGenomics' CEO? 116 employees have rated NeoGenomics Chief Executive Officer Douglas M. VanOort on Glassdoor.com. Douglas M. VanOort has an approval rating of 98% among the company's employees. This puts Douglas M. VanOort in the top 20% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of NeoGenomics own? Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Marvell Technology (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Inseego (INSG), PayPal (PYPL), Micron Technology (MU), Invitae (NVTA), CRISPR Therapeutics (CRSP) and AbbVie (ABBV). What is NeoGenomics' stock symbol? NeoGenomics trades on the NASDAQ under the ticker symbol "NEO." Who are NeoGenomics' major shareholders? NeoGenomics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Scout Investments Inc. (0.21%), Perkins Capital Management Inc. (0.16%), Oak Family Advisors LLC (0.08%), Yousif Capital Management LLC (0.06%), Comerica Bank (0.06%) and Nisa Investment Advisors LLC (0.04%). Insiders that own company stock include Bruce K Crowther, Douglas Matthew Brown, George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Kevin C Johnson, Lawrence Martin Weiss, Mark Mallon, Oort Douglas M Van, Robert J Shovlin, Steven C Jones and William Bonello. View institutional ownership trends. How do I buy shares of NeoGenomics? Shares of NEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is NeoGenomics' stock price today? One share of NEO stock can currently be purchased for approximately $12.69. How much money does NeoGenomics make? NeoGenomics (NASDAQ:NEO) has a market capitalization of $1.60 billion and generates $484.33 million in revenue each year. The medical research company earns $-8,350,000.00 in net income (profit) each year or ($1.32) on an earnings per share basis. How many employees does NeoGenomics have? The company employs 2,000 workers across the globe. How can I contact NeoGenomics? NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The official website for the company is www.neogenomics.com. The medical research company can be reached via phone at (239) 768-0600, via email at sjones@neogenomics.com, or via fax at 239-690-4237. This page (NASDAQ:NEO) was last updated on 2/3/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.